Compare Sanofi SA (SNY) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Victoria's Secret & Co — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Victoria's Secret & Co trades at $94.16 (market cap $7.48B). The key difference: Sanofi SA is far larger — about 13.9× Victoria's Secret & Co's market cap, and Sanofi SA pays a 5.55% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| SNY | VSXY | |
|---|---|---|
Market Cap | $104.30B | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $99.97 |
52-Week Low | $41.33 | $21.34 |
Enterprise Value | $124.19B | $10.13B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
VSXY trades at $94.6, down 5.37% today but near its 52-week high, with a bullish technical signal and strong support at $93. The company reported Q1 2026 EPS of $0.60, beating expectations, and shows improving net income margins. Analyst consensus is a Buy with a $91 target, while recent news highlights growth through data-driven marketing and international expansion.
Outlook is positive with earnings momentum and international growth, but risks include high valuation (P/E 37.51) and competitive pressures. Investors may find opportunity in continued execution, though margin sustainability and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
